Related Experiment Video
Updated: Jun 7, 2026
09:44
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
Patterns of retreatment by radiotherapy.
M B Barton1, H M Hudson, G Delaney
1South West Clinical School, University of New South Wales, Liverpool, Australia. Michael.Barton@sswahs.nsw.gov.au
Clinical Oncology (Royal College of Radiologists (Great Britain))
|October 29, 2010
Summary
Radiotherapy retreatment patterns vary significantly by cancer type, influencing service planning. Myeloma showed the highest retreatment rate, while brain cancers had the lowest, impacting future modeling and benchmarking.
Area of Science:
- Oncology
- Radiation Oncology
- Health Services Research
Background:
- Radiotherapy retreatment is a common practice for various cancers.
- Understanding retreatment patterns is crucial for optimizing cancer care services.
- Current data on retreatment variations by cancer type requires further analysis for service planning.
Purpose of the Study:
- To delineate radiotherapy retreatment patterns across different cancer types.
- To establish a foundation for modeling radiotherapy retreatment for improved service planning and benchmarking.
Main Methods:
- Analysis of an institutional database of patients receiving their first megavoltage radiotherapy (1997-2006).
- Inclusion of patient demographics, treatment dates, sites, and doses.
- Recoding of free-text treatment sites into standardized categories for analysis.
Main Results:
- A total of 7853 patients received 9859 radiotherapy episodes, with a retreatment ratio of 26 per 100 patients.
- Myeloma (1.05), unknown primary (0.41), lung (0.34), and melanoma (0.32) had the highest mean retreatments.
- Brain cancers exhibited the lowest mean retreatment rate (0.06); median time between treatments varied significantly by cancer type.
Conclusions:
- Radiotherapy retreatment ratios are influenced by follow-up duration and specific cancer type.
- Significant variations in retreatment frequency exist, from central nervous system malignancies to myeloma.
- Findings support the development of predictive models for radiotherapy retreatment to enhance service planning and resource allocation.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...